Influenza Diagnostics Market size was valued at USD 1.07 billion in 2021 and is poised to grow from USD 1.1 billion in 2022 to USD 1.46 billion by 2030, growing at a CAGR of 3.5% in the forecast period (2023-2030).
Influenza is simply referred to as the flu. It is an infectious disease of the upper respiratory tract caused by the influenza virus. The seasonal influenza virus is classified into three types: Influenza B, Influenza A, And Influenza C, which are characterized by two major surface proteins: hemagglutinin (HA) and neuraminidase (NA). Different serotypes are observed as a result of differences in these surface proteins, which determine the antibody response to the viruses. Because influenza is a highly contagious and communicable disease, infected patients who serve as carriers of the disease can easily transmit the disease in public places.
The disease burden varies by region, with temperate climate regions experiencing seasonal influenza outbreaks. In tropical regions where influenza occurs all year, causing constant outbreaks, disease management and treatment are difficult. Rising demand for rapid disease diagnosis, rising influenza prevalence, and increased influenza research for diagnostic technologies are driving the Influenza Diagnostics Market growth.
Read more: https://www.skyquestt.com/report/influenza-diagnostics-market